Roche CEO: No Layoff Plans, Business Healthy and Stable

The CEO of Swiss pharmaceutical company Roche Holding AG (stock code: ROG.S), Thomas Schinecker, emphasized in an interview with the Swiss newspaper NZZ am Sonntag that the company currently has no layoff plans and that its business is in good shape. Despite Roche's stock price being significantly lower than its peak in April 2022, and facing some setbacks in the development of cancer and other disease treatments, Schinecker clearly stated that the company's employee count will remain stable and may even see a slight increase.

Schinecker noted, “I can say with certainty that our business is very healthy. We do not have growth issues.” He also mentioned that Roche's R&D budget remains stable, with no growth. Regarding the company's planned anti-obesity drug, Schinecker expects it may be available by 2029 or earlier.

Looking ahead, particularly against the backdrop of recent difficulties in the German economy, Roche's CEO stated that the European market still faces challenges. He commented, “The U.S. economy is growing, but the situation in China is more difficult right now.” He added, “In Europe, we need some time to get out of the difficulties.”